MA46909A - Médicament thérapeutique ou médicament prophylactique pour une néphropathie diabétique - Google Patents

Médicament thérapeutique ou médicament prophylactique pour une néphropathie diabétique

Info

Publication number
MA46909A
MA46909A MA046909A MA46909A MA46909A MA 46909 A MA46909 A MA 46909A MA 046909 A MA046909 A MA 046909A MA 46909 A MA46909 A MA 46909A MA 46909 A MA46909 A MA 46909A
Authority
MA
Morocco
Prior art keywords
therapeutic
diabetic nephropathy
prophylactic drug
prophylactic
drug
Prior art date
Application number
MA046909A
Other languages
English (en)
Inventor
Takashi Shirakura
Yoshiki Tsubosaka
Shunsuke Tsujimoto
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MA46909A publication Critical patent/MA46909A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046909A 2016-11-28 2017-11-27 Médicament thérapeutique ou médicament prophylactique pour une néphropathie diabétique MA46909A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016229972 2016-11-28

Publications (1)

Publication Number Publication Date
MA46909A true MA46909A (fr) 2021-05-05

Family

ID=62195148

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046909A MA46909A (fr) 2016-11-28 2017-11-27 Médicament thérapeutique ou médicament prophylactique pour une néphropathie diabétique

Country Status (17)

Country Link
US (1) US20190374515A1 (fr)
EP (1) EP3545954A4 (fr)
JP (2) JP6861726B2 (fr)
KR (1) KR20190073473A (fr)
CN (1) CN109982697A (fr)
AU (1) AU2017364804A1 (fr)
BR (1) BR112019008388A2 (fr)
CA (1) CA3039890A1 (fr)
CL (1) CL2019001421A1 (fr)
CO (1) CO2019005512A2 (fr)
IL (1) IL266311A (fr)
MA (1) MA46909A (fr)
MX (1) MX2019005867A (fr)
PH (1) PH12019501027A1 (fr)
RU (1) RU2735538C1 (fr)
TW (1) TW201828939A (fr)
WO (1) WO2018097294A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282934A (zh) * 2005-10-07 2008-10-08 安斯泰来制药株式会社 三芳基羧酸衍生物
TWI437986B (zh) * 2008-01-31 2014-05-21 R Tech Ueno Ltd 噻唑衍生物及使用該衍生物作為ｖａｐ－１抑制劑之用途
UA112632C2 (uk) * 2010-06-16 2016-10-10 Такеда Фармасьютикалз Ю.Ес.Ей., Інк. Дозована форма з модифікованим вивільненням фебуксостату (варіанти)
JP5862897B2 (ja) 2010-11-01 2016-02-16 株式会社三和化学研究所 腎機能障害の予防又は治療に用いる医薬
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
CN103848796A (zh) * 2012-11-30 2014-06-11 镇江新元素医药科技有限公司(中外合资) 一类氘代2-苯基噻唑化合物及其药物组合物
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
US11406713B2 (en) * 2013-03-15 2022-08-09 Xortx Therapeutics, Inc. Xanthine oxidase inhibitor formulations
KR102259713B1 (ko) * 2014-07-30 2021-06-01 데이진 화-마 가부시키가이샤 크산틴옥시다아제 저해약

Also Published As

Publication number Publication date
EP3545954A4 (fr) 2019-12-04
EP3545954A1 (fr) 2019-10-02
JP2021028335A (ja) 2021-02-25
CN109982697A (zh) 2019-07-05
TW201828939A (zh) 2018-08-16
US20190374515A1 (en) 2019-12-12
CO2019005512A2 (es) 2019-07-31
BR112019008388A2 (pt) 2019-07-09
WO2018097294A1 (fr) 2018-05-31
RU2735538C1 (ru) 2020-11-03
CA3039890A1 (fr) 2018-05-31
IL266311A (en) 2019-06-30
MX2019005867A (es) 2019-08-14
CL2019001421A1 (es) 2019-08-30
JPWO2018097294A1 (ja) 2019-07-11
JP6861726B2 (ja) 2021-04-21
PH12019501027A1 (en) 2019-12-16
KR20190073473A (ko) 2019-06-26
AU2017364804A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
BR112018009951A2 (pt) fármaco oftálmico
DK3463465T3 (da) Exosomer omfattende terapeutiske polypeptider
DK3328880T3 (da) Terapeutiske midler
MA40764A (fr) Agent thérapeutique induisant une cytotoxicité
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3722274T3 (da) 2-perfluorbutylpentan til oftalmisk indgivelse
MA41449A (fr) Polythérapies pour le traitement de cancers
BR112016015838A2 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
BR112016026879A2 (pt) Composição farmacêutica líquida
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
MA39483A (fr) Agents thérapeutiques cibles
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112018005409A2 (pt) terapêutica de glicodirecionamento.
DK3532029T3 (da) Flydende farmaceutisk sammensætning
FR3036518B1 (fr) Inversion pour contrainte tectonique
DK3393478T3 (da) Kombinationsterapi
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
DK3463345T3 (da) Farmaceutiske kombinationer
FR3017684B1 (fr) Profile pour joint
DK3111934T3 (da) Progressions-hæmmende eller -forbedrende middel til kronisk nyresygdom
DK3329004T3 (da) Terapeutiske oligonukleotider